Evaxion Biotech AS EBITDA per Share

What does Evaxion Biotech AS do? Evaxion A/S develops AI-powered immunology vaccines, including EVX-01 in phase 2 trials for advanced melanoma, EVX-03 for solid tumors, and EVX-04 in phase 1 for acute myeloid leukemia. The company also has pre-clinical programs like EVX-B1 targeting S. aureus infections, EVX-B2 for gonorrhea, EVX-B3 for recurring bacterial infections, and EVX-V1 for cytomegalovirus. These products are developed for clinical and therapeutic use in cancer and infectious disease treatment. The company focuses on developing vaccines through clinical and pre-clinical stages, with EVX-01, EVX-03, and EVX-04 in active trials. EVX-B1, EVX-B2, EVX-B3, and EVX-V1 are in pre-clinical development for prophylactic use against bacterial and viral infections. The company's pipeline targets healthcare providers and patients seeking advanced treatments for cancer and infectious diseases. Evaxion A/S is a clinical-stage biotech company based in Horsholm, Denmark, incorporated in 2008. It operates under the name Evaxion A/S since May 2025, having previously been known as Evaxion Biotech A/S. The company's revenue model relies on developing and advancing its vaccine candidates through clinical trials to potential partnerships or commercialization. Evaxion Biotech AS is one of the most popular companies on Eulerpool.